Sonni Elliott, MD
Psychiatry · Leawood, KSNPI 1609066240
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,960 of the $22,082 with a category attached, or 90.4%. Alkermes, Inc. accounts for 97.5% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $20,680 and has fallen 99.5% since, to $102 in 2025. Among psychiatry clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 70 payments — averaging $315.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$22K
- Lundbeck LLC$135
- AbbVie$63
- Vanda Pharmaceuticals Inc.$45
- Sunovion Pharmaceuticals Inc.$43
- Neurocrine Biosciences, Inc.$42
- plus $219 from 8 others
What the payments were for
- Speaking & faculty fees$19,96090%
- Travel & lodging$3742%
- Food & beverage$1,7488%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$83,283
- ARISTADA INITIO$20,821
How this compares
$22,082 in reported general payments places this provider in the 95th percentile of 259 psychiatry providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Vilazodone Hcl | 14 | $2,258 |
| Ramelteon | 12 | $1,383 |
| Naltrexone Hcl | 12 | $406 |
| Doxepin Hcl | 11 | $290 |
| Bupropion XlBupropion Hcl | 15 | $223 |
| Clonazepam | 25 | $150 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 11 | $134 |
| Lamotrigine | 24 | $127 |
| Fluoxetine Hcl | 12 | $51 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Leawood
- Kevin MaysLeawood$548K
- Andrew SegravesLeawood$19K
- Michael EversonLeawood$19K
- Steven SegravesLeawood$13K
- Lolitta AznaurovaLeawood$11K
- Christopher van HornLeawood$10K
- Sherman ColeLeawood$8K
- Erick BrownLeawood$8K
- Wade HachinskyLeawood$7K
- Salma VelazquezLeawood$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.